Novel derivatives of substituted terahydro m-oxazines, their process of preparation and their therapeutic application

ABSTRACT

IN WHICH X is oxygen or sulfur and R is methoxy, phenoxy or morpholino, are prepared by cyclizing the corresponding 1substituted-4-amino-2-butanol with a compound containing a   GROUP. The compounds possess analgesic, spasmolytic, vasodilatory, hypertensive and antidepressive properties.   Compounds of the formula D R A W I N G

United States Patent [191 Fauran et al.

[ 1 NOVEL DERIVATIVES OF SUBSTITUTED TETRAHYDRO M-OXAZINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC APPLICATION [75] Inventors: Claude P. Fauran; Colette Douzon;

Guy M. Raynaud, all of Paris; Micheline Y. Sergant, Clamart, all of France [73] Assignee: Delalande S.A., Courbevoie, France [22] Filed: May 5, 1972 1 [21] Appl. No.: 250,741

[30] Foreign Application Priority Data OTHER PUBLICATIONS Humphreys et al., J. Chem. Soc. (London), p. 1298-l- 304 (1931).

[ June 28, 1974 Primary Examinerl-larry I. Moatz Attorney, Agent, or Firm-Woodhams, Blanchard &

Flynn [5 7] ABSTRACT Compounds of the formula in which X is oxygen or R is methoxy, phenoxy or morpholino, are prepared by cyclizing the corresponding l-substituted-4-amino-Z-butanol with a compound containing a group. The compounds possess analgesic, spasmolytic, vasodilatory, hypertensive and antidepressive properties.

10 Claims, N0 Drawings X represents an oxygen or sulfur atom, and R represents a methoxy, phenoxy or morpholino radical. The process according to the invention consists in cyclising an amino-alcohol of the general formula:

R-CH;

in which R has the same signification as in formula I, with a compound containing the group in which X has the same signification as in formula 1.

More particularly, when X represents an oxygen atom, the compound of formula 111 may be phosgene or ethyl carbonate. When X is a sulfur atom, the compound of formula 111 may be thiophosgene or the his (imidazolyl) thionc.

The following preparations are given by way of examplc to illustrate the invention. EXAMPLE 1 6-Phenoxymethyl tetrahydro m-oxazine-2-one. (Code No. 69218) 36g. of l-phenoxy-4-amino-2-butanol, in solution in 150 ml of benzene, was introduced into a 1 litre balloon-flask and heated to 30C. 200 ml of a solution of 20% phosgene in toluene and 500 ml of a solution of 10% potassium carbonate were simultaneously added thereto, drop by drop and with good agitation. The temperature increases rapidly. The flask is cooled so that the temperature increase does not exceed 30C. The product so formed, which is insoluble, is dried and recrystallized from dioxan. Melting point 145C Yield 78% Empirical formula C H NO Elementary analysis:

Calculated Found EXAMPLE 2 A solution of 5g. of sodium methylate in ml of toluene is first prepared. This solution is heated to boiling and a mixture of 1-morph01ino-4-amino 2-butanol (35g) and ethyl carbonate (38g) is slowly added thereto. The ethanol is distilled off as it is formed. The solvents are removed. The residue is taken up in ethanol and treated with hydrochloric acid, the hydrochloride formed is dried and crystallised from 96 ethanol.

Melting point 240C (with decomposition) Yield 50% Empirical formula C I-I Cl N 0 Elementary analysis:

c H N Calculated 45.67 7.24 11.84

Found 45.55 7.30 11.84

EXAMPLE 3 6-Methoxymethyl tetrahydro-m-oxazine-Z-one (Code No. 70108) This compoundis obtained according to the identical mode of operation described in Example 2, using 1-methoxy-4-amino-2-butanol and ethyl carbonate. -Melting point 60C Yield 35% Empirical formula C I-I NO Elementary analysis:

1 C H N Calculated 49.64 7.64 9.65 Found 49.53 7.76 9.81

EXAMPLE 4 Elementary analysis:

C H N Calculated 59.17 5.87 6.27 Found 59.15 5.77 6.43

EXAMPLE 5 6-Morpholinomethyl tetrahydro-m-oxazine-2-thion (Code No. 70327) 4 35g of l-morpholino-4-amino-2-butanol are dissolved in 1.5 l of water and 67g of sodium bicarbonate is added thereto. The mixture is heated to 40C and 46g of thiophosgene is added thereto; after 3 hours in contact,'the solution is concentrated under reduced pressure, and extracted with chloroform. After having concentrated the solution, the product obtained is recrystallised frorn isopropyl alcohol.

Melting point 133C Yield 25% Empirical formula C H N O S 6-Methoxymethyl tetrahydro-m-oxazine-2-thione (Code No. 70400) This compound is obtained according to the identical mode of operation described in Example 5, using l-methoxy-4-amino-2-butanol and thiophosgene. Melting point 88C Yield 21% Empirical formula C H NO S Elementary analysis:

C H N Calculated 44.70 6.88 8.69 Found 44.73 7.0] 8.71

TABLE I Percentage protection Code No. of compound tested Dose administered I00 mg/kg/PO so mg/kg/PO 100 mg/kg/PO 2. Spasmolytic properties a The compounds of Formula 1, introduced in the conserving medium, are capable of opposing the contractural action of barium chloride on the isolated duodenum of the rat. This activity is evaluated by taking papaverine as standard.

By way of example, the spasmolytic activity of Compound No. 69218 is equal to three times that of papaverine.

3. Vasodilatatory properties The compounds of formula I are capable of augmenting the flow of the coronary vessels of the isolated heart of a guinea pig when said compounds are added in the perfusion liquid of said organ.

By way of example, at a concentration of 2.5 Mg/ml/mn in the perfusion liquid, the compound No. 69233 showed an augmentation of the coronary flow.

4. Hypertensive properties Administered by intraveinous means on the anaesthetized rat, the compounds of formula I provoke an increase in the arterial pressure.

Moreover, in a dose of 2 mg/kg/I.V., the compound No. 70108 produced a 30% increase in the arterial pressure of a rat for a period in excess of 30 minutes.

5. Antidepressive properties The compounds of formula I, preventatively administered by oral means to the mouse, are capable of opposing the ptosis provoked by the injection of reserpine.

By way of example, the administration of 50 mg/kg/PO of compound No. 70264 reduces the ptosis by 80%.

One can see from the results shown in the following Table II that the difference-between the pharmacologically active dose and the lethal dose is sufficiently great to permit the compounds of formula I to be used in therapeutics.

TABLE II Code No. of Dose administered Percentage mortality compound tested 69218 2500 mg/kg/PO 50 69233 I500 mg/kg/PO 0 70108 2000 mg/kg/PO 0 t 70264 470 mg/kg/PO 50 2200 mg/kg/PO 50 The compounds of formula I are useful in the treatment of pain, digestive and other spasms, diverse circulatatory insufficiencies, hypotensions and depressive syndromes. v

They may be administered by oral means in the form of tablets, dragees and gelules containing 50 to 400 mg of active ingredient (3 to 5 times a day) and by rectal means in the form of suppositories containing 50 to 200 mg of active ingredient (l or 2 times a day).

Accordingly, the present invention also relates to a therapeutic composition comprising a compound of the general formula I together with a therapeutically acceptable carrier.

What we claim is:

. 1. A compound of the formula in which X is oxygen or sulfur, and

R is methoxy, phenoxy or morpholino.

2. A compound according to claim 1, in which R is phenoxy.

3. A compound according to claim 2, in which X is sulfur.

4. A compound according to claim 2, in which X is oxygen. 1

5. A compound according to claim 1, in which R is methoxy.

6. A compound according to claim 5, in which X is sulfur.

7. A compound according to claim 5, in which X is oxygen.

8. A compound according to claim 1, in which R is morpholino.

9. A compound according to claim 8, in which X is sulfur.

10. A compound according to claim 8, in which X is oxygen. 

2. A compound according to claim 1, in which R is phenoxy.
 3. A compound according to claim 2, in which X is sulfur.
 4. A compound according to claim 2, in which X is oxygen.
 5. A compound according to claim 1, in which R is methoxy.
 6. A compound according to claim 5, in which X is sulfur.
 7. A compound according to claim 5, in which X is oxygen.
 8. A compound according to claim 1, in which R is morpholino.
 9. A compound according to claim 8, in which X is sulfur.
 10. A compound according to claim 8, in which X is oxygen. 